专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4690931A Therapeutically useful 1-phenyl-2-piperidinoalkanol derivatives 失效
标题翻译：治疗上有用的1-苯基-2-哌啶子基链烷醇衍生物
公开(公告)号：US4690931A
公开(公告)日：1987-09-01
申请号：US773926
申请日：1985-09-09
申请人： Alexander Wick , Jonathan Frost , Bernard Gaudilliere , Jean Bertin , Regis Dupont , Jean Rousseau
发明人： Alexander Wick , Jonathan Frost , Bernard Gaudilliere , Jean Bertin , Regis Dupont , Jean Rousseau
IPC分类号： C07D211/12 , A61K31/445 , A61K31/451 , A61P9/08 , A61P25/24 , A61P25/26 , A61P25/28 , C07C45/00 , C07C45/45 , C07C45/54 , C07C45/63 , C07C45/71 , C07C49/76 , C07C49/80 , C07C49/825 , C07C49/84 , C07C63/70 , C07C67/00 , C07C69/76 , C07D211/14 , C07D211/18 , C07D211/22 , C07D211/26 , C07D211/28 , C07D211/30 , C07D211/32 , C07D211/62 , C07D213/50 , C07D213/78 , C07D317/18 , C07D317/30
CPC分类号： C07D211/22 , C07C45/004 , C07C45/45 , C07C45/54 , C07C45/63 , C07C45/71 , C07C49/80 , C07C49/825 , C07C49/84 , C07D211/14 , C07D211/18
摘要： Compounds of the formula: ##STR1## wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, alkyl, hydroxyl, alkyoxy, benzyloxy, alkanoyloxy, or benzoyloxy, or when R.sub.2 is hydroxyl or methoxy in the 4-position and R.sub.3 is hydrogen, R.sub.1 may also represent hydroxymethyl carbamoyl or alkoxycarbonyl,R.sub.2 is hydrogen, halogen, alkyl, hydroxyl, or alkoxy,R.sub.3 is hydrogen or alkyl,R.sub.4 is alkyl (in which case the compounds are (.+-.)-erythro) or when R.sub.3 represents hydrogen, R.sub.4 may also be hydrogen, and R.sub.5 is hydrogen, halogen, alkyl, alkoxy, or three methoxy groups in the 3-, 4- and 5-positions and pharmaceutically acceptable acid addition salts thereof, with the exclusion of compounds wherein:(a) one of R.sub.1 and R.sub.2 is in the 4-position and is hydroxyl, alkoxy or benzyloxy, the other is in the 3-position and is hydrogen, hydroxyl, alkoxy or benzyloxy, and R.sub.3 and R.sub.5 are hydrogen and wherein:(b) R.sub.1 is in the 4-position and is halogen, R.sub.4 is methyl and R.sub.2, R.sub.3 and R.sub.5 are hydrogen, are useful as medicaments.
摘要翻译：下式的化合物：其中R 1为氢，卤素，三氟甲基，烷基，羟基，烷氧基，苄氧基，烷酰氧基或苯甲酰氧基，或当R 4为4-位的羟基或甲氧基且R 3为氢时， R1还可以表示羟甲基氨基甲酰基或烷氧基羰基，R2是氢，卤素，烷基，羟基或烷氧基，R3是氢或烷基，R4是烷基（在这种情况下，化合物是（+/-） - 赤式）氢，R 4也可以是氢，R 5是氢，卤素，烷基，烷氧基或三个甲氧基的3-，4-和5-位及其药学上可接受的酸加成盐，其中：（ a）R1和R2中的一个是4-位，羟基，烷氧基或苄氧基，另一个是3-位，是氢，羟基，烷氧基或苄氧基，R3和R5是氢，其中：（b ）R1为4-位且为卤素，R4为甲基，R2，R3和R5为氢，可用作药物。

2. 发明授权

US4661498A Furo 3,2-c pyridine derivatives and their use in treating depression and cerebral ischemia 失效
标题翻译： Furo 3,2-c吡啶衍生物及其在治疗抑郁症和脑缺血中的应用
公开(公告)号：US4661498A
公开(公告)日：1987-04-28
申请号：US780453
申请日：1985-09-26
申请人： Alexander Wick , Jonathan Frost , Jean Bertin
发明人： Alexander Wick , Jonathan Frost , Jean Bertin
IPC分类号： A61K31/435 , A61P25/24 , A61P25/26 , C07D211/72 , C07D211/74 , C07D491/04 , C07D491/048 , A61K31/44
CPC分类号： C07D491/04 , C07D211/72 , C07D211/74
摘要： Compounds of general formula (I) ##STR1## wherein R1 represents a phenyl, halophenyl, methylphenyl, ethylphenyl, methoxyphenyl, trifluoromethylphenyl or naphthyl group, R2 represents hydrogen or a methyl or phenyl group, and R3 represents hydrogen or a benzyl group, except compounds in which R1 is a phenyl or 4-fluorophenyl group, R2 is hydrogen and R3 is hydrogen or a benzyl group, and their pharmaceutically acceptable acid addition salts have useful anti-depressant and anti-ischaemic properties.
摘要翻译：通式（I）的化合物其中R 1表示苯基，卤代苯基，甲基苯基，乙基苯基，甲氧基苯基，三氟甲基苯基或萘基，R 2表示氢或甲基或苯基，R 3表示氢或苄基除了R1是苯基或4-氟苯基，R2是氢和R3是氢或苄基的化合物以外，其药学上可接受的酸加成盐具有有用的抗抑郁和抗缺血性质。

3. 发明授权

US5620990A Alpha-(4-chlorophenyl)-4-[(4-fluorphenyl)-methyl]piperidine-1-ethanol esters, their preparation and their therapeutic application 失效
标题翻译： α-（4-氯苯基）-4 - [（4-氟苯基） - 甲基]哌啶-1-乙醇酯，其制备及其治疗应用
公开(公告)号：US5620990A
公开(公告)日：1997-04-15
申请号：US499918
申请日：1995-07-11
申请人： Jean P. Thenot , Jonathan Frost , Patrick Lardenois , Maria C. Renones , Alexander Wick
发明人： Jean P. Thenot , Jonathan Frost , Patrick Lardenois , Maria C. Renones , Alexander Wick
IPC分类号： A61K31/445 , A61P1/08 , A61P7/02 , A61P9/00 , A61P9/08 , A61P9/10 , A61P11/16 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/06 , A61P25/08 , A61P25/26 , A61P25/28 , A61P27/02 , A61P37/00 , A61P43/00 , C07D211/18 , C07D211/08 , C07D211/34
CPC分类号： C07D211/18
摘要： The present invention provides a piperidine derivative of formula (I) ##STR1## in which R represents a straight- or branched-chain (C.sub.1 -C.sub.19)alkyl group, a straight- or branched-chain (C.sub.2 -C.sub.19)alkenyl group, a (C.sub.3 -C.sub.6)cycloalkyl group, a cycloalkylmethyl group in which the cycloalkyl moiety has from three to six carbon atoms, a phenyl group which is optionally substituted by a halogen atom or a phenyl methyl group which is optionally substituted by a halogen atom, or an addition salt thereof, in the form of an optically pure enantiomer or of a mixture of enantiomers, a process for making them and their therapeutic application.
摘要翻译：本发明提供式（I）的哌啶衍生物，其中R表示直链或支链（C1-C19）烷基，直链或支链（C2-C19）烯基基团，（C 3 -C 6）环烷基，环烷基部分具有3至6个碳原子的环烷基甲基，任选被卤素原子取代的苯基或任选被卤素取代的苯基甲基原子或其加成盐，以光学纯对映体或对映异构体的混合物的形式，其制备方法及其治疗应用。

4. 发明授权

US4621087A Anti-anoxic furo- or pyrrolo-pyridine compounds and pharmaceutical compositions containing them 失效
标题翻译：抗缺氧呋喃或吡咯吡啶化合物和含有它们的药物组合物
公开(公告)号：US4621087A
公开(公告)日：1986-11-04
申请号：US748765
申请日：1985-06-26
申请人： Alexander Wick , Jonathan Frost , Patrick Lardenois
发明人： Alexander Wick , Jonathan Frost , Patrick Lardenois
IPC分类号： A61K31/435 , A61P9/00 , A61P25/24 , A61P25/26 , A61P25/28 , C07D211/78 , C07D471/04 , C07D491/04 , C07D491/048 , A61K31/44
CPC分类号： C07D471/04 , C07D211/78 , C07D491/04
摘要： Pyridine derivatives of the general formula (I) ##STR1## in which X is --O-- or --NH--, R.sub.1 is a phenyl group optionally substituted by one or two halogen atoms or a methyl, ethyl, trifluoromethyl, methoxy or phenyl group or, when R.sub.2 is not a benzyl group, an amino group, or is a naphthyl or benzodioxanyl group, and R.sub.2 is hydrogen or a benzyl group, or when X is --O--, R.sub.2 can also be a methyl or ethyl group, and their pharmaceutically acceptable acid addition salts are useful as antianoxics.
摘要翻译：通式（I）的吡啶衍生物其中X为-O-或-NH-，R 1为任选被一个或两个卤素原子取代的苯基或甲基，乙基，三氟甲基，甲氧基或苯基，或者当R2不是苄基，氨基或萘基或苯并二氧杂环戊烷基，R2是氢或苄基时，或当X是-O-时，R2也可以是甲基或乙基，及其药学上可接受的酸加成盐可用作抗氧化剂。

5. 发明授权

US5034401A Derivatives of (1-hydroxy-2-piperidylalkyl-indol-2-ones, 2-quinolinones, 2-benzo(B)azapinones, benzimidazol-2-ones, and quinazolin-2-ones, their preparation and their application in therapeutics 失效
标题翻译：（1-羟基-2-哌啶基烷基 - 吲哚-2-酮，2-喹啉酮，2-苯并（B）吖庚因酮，苯并咪唑-2-酮和喹唑啉-2-酮的衍生物，其制备及其在治疗中的应用
公开(公告)号：US5034401A
公开(公告)日：1991-07-23
申请号：US378094
申请日：1989-07-11
申请人： Jonathan Frost , Patrick Lardenois , Jean Bertin , Alfred Saarmets , Corinne Rousselle
发明人： Jonathan Frost , Patrick Lardenois , Jean Bertin , Alfred Saarmets , Corinne Rousselle
IPC分类号： A61K31/4427 , A61K31/443 , A61K31/445 , A61P25/00 , A61P25/28 , A61P35/00 , C07D401/06 , C07D401/14 , C07D405/14 , C07D491/107
CPC分类号： C07D401/06 , C07D401/14
摘要： A compound, in the form of a pure optical isomer or a mixture thereof, of formula (I): ##STR1## in which: Z represents a group of formula --CH.sub.2 --, --C(CH.sub.3).sub.2 --, --CH.dbd.CH--, --(CH.sub.2).sub.2 --, --(CH.sub.2).sub.3 --, --NH-- or --N(CH.sub.3)CH.sub.2 --, in which the nitrogen is bonded to the carbonyl group;R1 represents hydrogen or a C.sub.1 -C.sub.4 alkyl group;R2 represents hydrogen or a methyl group; andR3 represents:a phenoxy group which is unsubstituted or substituted by a halogen or a methyl group,a naphthyloxy group,a phenylmethyl group substituted by a halogen or a methyl group,an unsubstituted phenylmethyl group when Z does not representa group of formula --CH.dbd.CH-- or --(CH.sub.2).sub.2 --,a bis (4-fluorophenyl)-methyl group,a phenylmethoxy group which is unsubstituted or substituted by a halogen or a methyl group,a (2-naphthyl)methoxy group,a phenoxymethyl group which is unsubstituted or substituted by a halogen or a methyl group, ora pyridinyloxy group, andR4 represents hydrogen; orR3 and R4 form, together and with the piperidine ring to which they are attached, a spiro (2,3-dihydrobenzofuran-2,4'-piperid-1-yl) group; or a pharmacologically acceptable acid addition salt thereof.
摘要翻译：式（I）的纯旋光异构体或其混合物形式的化合物：其中：Z表示式-CH 2 - ， - C（CH 3）2 - ， - CH = CH - ， - （CH 2）2 - ， - （CH 2）3 - ， - NH-或-N（CH 3）CH 2 - ，其中氮键合到羰基上; R1表示氢或C1-C4烷基; R2表示氢或甲基; R3表示：未被取代或被卤素或甲基取代的苯氧基，萘氧基，被卤素或甲基取代的苯基甲基，当Z不表示式 - CH = CH-或 - （CH 2）2 - ，双（4-氟苯基） - 甲基，未被取代或被卤素或甲基取代的苯基甲氧基，（2-萘基）甲氧基，苯氧基甲基未取代或被卤素或甲基取代的基团，或吡啶氧基，R4表示氢; 或者R 3和R 4与它们所连接的哌啶环一起形成螺（2,3-二氢苯并呋喃-2,4'-哌啶-1-基）基团; 或其药理学上可接受的酸加成盐。

6. 发明授权

US07135569B2 Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters 有权
标题翻译：制备吡啶基和嘧啶基单氟化β-酮酯的方法
公开(公告)号：US07135569B2
公开(公告)日：2006-11-14
申请号：US11221023
申请日：2005-09-07
申请人： Jonathan Frost
发明人： Jonathan Frost
IPC分类号： C07D239/26 , C07D213/127
CPC分类号： C07D239/26 , C07D213/55
摘要： The present invention relates to a process for preparing pyridinyl and pyrimidinyl mono-fluorinated beta keto esters of formula (I): wherein: R1 represents a pyridine ring or a pyrimidine ring, the rings being optionally substituted by a C3-6 cycloalkyl group, a C1-4 alkyl group, a C1-4 alkoxy group, a benzyl group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group or ahalogenatom; and R3 represents a C1-6 alkyl group; by reacting with fluorine a compound of formula (II) wherein R1, R2 and R3 have the same meaning as defined above.
摘要翻译：本发明涉及制备式（I）的吡啶基和嘧啶基单氟化β-酮酯的方法：其中：R1表示吡啶环或嘧啶环，该环任选被C 3-6 C 1-4烷基，C 1-4烷氧基，苄基或卤素原子; C 1-4烷基，C 1-4烷基，C 1-4烷基， R 2表示氢原子，C 1-6烷基或卤素原子; 并且R 3表示C 1-6烷基; 通过与氟反应，其中R 1，R 2和R 3具有与上述相同的含义的式（Ⅱ）化合物。

7. 发明授权

US5550162A N-(-3-aminopropyl)-N-phenyl-5,6,7,8-tetrahydro-naphthalene-2-carboxamide derivatives, their preparation and their therapeutic use 失效
标题翻译： N-（3-氨基丙基）-N-苯基-5,6,7,8-四氢 - 萘-2-甲酰胺衍生物，其制备及其治疗用途
公开(公告)号：US5550162A
公开(公告)日：1996-08-27
申请号：US382578
申请日：1995-02-20
申请人： Jonathan Frost , Pascal George , Patrick Pasau , R egine Bartsch , Corinne Rousselle , Paul H. Williams , Jean C. Muller
发明人： Jonathan Frost , Pascal George , Patrick Pasau , R egine Bartsch , Corinne Rousselle , Paul H. Williams , Jean C. Muller
IPC分类号： A61K31/165 , A61K31/38 , A61K31/395 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/435 , A61K31/47 , A61K31/472 , A61K31/55 , A61P3/00 , A61P3/14 , A61P9/00 , A61P9/08 , A61P9/10 , A61P25/00 , A61P25/28 , A61P37/00 , C07C233/11 , C07C233/78 , C07C233/80 , C07C233/88 , C07D209/44 , C07D217/04 , C07D217/24 , C07D223/16 , C07D233/16 , C07D471/04 , C07D495/04 , C07D513/04 , C07C233/65
CPC分类号： C07D223/16 , C07C233/78 , C07C233/88 , C07D209/44 , C07D217/04 , C07D471/04 , C07D495/04 , C07C2102/08 , C07C2102/10
摘要： Compounds of the formula: ##STR1## in which R.sub.1 represents a hydrogen or halogen atom or a methyl or C.sub.1 -C.sub.4 alkoxy group, R'.sub.1 represents a hydrogen or halogen atom, R".sub.1 represents a hydrogen atom or a methoxy group, R.sub.3 represents a C.sub.1 -C.sub.3 alkyl group, R.sub.4 represents a 2,3-dihydro-1H-inden-2-yl, 2,3-dihydro-1H-inden-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group, or R.sub.3 and R.sub.4 together form, with the adjacent nitrogen atom, a 1,2,3,4-tetrahydroisoquinol-2-yl, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl, 5,8-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-3-yl, 4,5,6,7-tetrahydrothieno[2,3-c]pyrid-6-yl, 2,3-dihydro-1H-isoindol-2-yl or 2,3,4,5-tetra-hydro-1H-3-benzazepin-3-yl, group are useful in the treatment of cerebral disorders.
摘要翻译：下式的化合物：其中R 1表示氢或卤素原子或甲基或C 1 -C 4烷氧基，R 1表示氢或卤素原子，R“1表示氢原子或甲氧基，R 3表示C 1 -C 3烷基，R 4表示2,3-二氢-1H-茚-2-基，2,3-二氢-1H-茚-1-基或1,2,3,4 四氢萘-1-基或R3和R4一起与相邻的氮原子一起形成1,2,3,4-四氢异喹啉-2-基，6,7-二甲氧基-1,2,3,4-四氢萘-1-基，四氢异喹啉-2-基，5,8-二甲氧基-1,2,3,4-四氢异喹啉-2-基，1,2,3,4-四氢-9H-吡啶并[3,4-b] -1,2,3,4-四氢-9H-吡啶并[4,3-b]吲哚-3-基，4,5,6,7-四氢噻吩并[2,3-c]吡啶-6-基， 2,3-二氢-1H-异吲哚-2-基或2,3,4,5-四氢-1H-3-苯并氮杂-3-基可用于治疗脑部疾病。

8. 发明授权

US4983607A Quinolinone derivatives and their preparation in therapy 失效
标题翻译：喹啉酮衍生物及其在治疗中的应用
公开(公告)号：US4983607A
公开(公告)日：1991-01-08
申请号：US417970
申请日：1989-10-10
申请人： Philippe Manoury , Daniel Obitz , Michel Peynot , Jonathan Frost
发明人： Philippe Manoury , Daniel Obitz , Michel Peynot , Jonathan Frost
IPC分类号： C07D215/22 , A61K31/495 , A61P43/00 , C07D215/227 , C07D401/12
CPC分类号： C07D215/227 , C07D401/12
摘要： A quinolinone derivative which is a compound of formula (I): ##STR1## in which: R.sub.1 and R.sub.2 are each, independently of one another, a hydrogen or halogen atom or a (C.sub.1-4)alkyl radical;R.sub.3 is a hydrogen atom or a (C.sub.1-4)alkyl radical;R.sub.4 is an unsubstituted or substituted naphthyl, tetrahydronaphthyl, benzyl, phenyl, pyridyl, isoquinolyl or benzoyl radical; and X and Y are each a hydrogen atom or together form a bond; or a pharmaceutically acceptable acid addition salt thereof and, when X and Y are each a hydrogen atom, the diastereoisomers and enantiomers thereof.
摘要翻译：作为式（I）化合物的喹啉酮衍生物：其中：R 1和R 2各自独立地为氢或卤素原子或（C 1-4）烷基; R3是氢原子或（C1-4）烷基; R4是未取代或取代的萘基，四氢萘基，苄基，苯基，吡啶基，异喹啉基或苯甲酰基; X和Y各自为氢原子或一起形成键; 或其药学上可接受的酸加成盐，当X和Y各自为氢原子时，其非对映异构体和对映异构体。

9. 发明授权

US5447928A Benzoxazine derivatives and their application in therapy 失效
标题翻译：苯并恶嗪衍生物及其在治疗中的应用
公开(公告)号：US5447928A
公开(公告)日：1995-09-05
申请号：US201233
申请日：1994-02-24
申请人： Howard Williams , Lydia Zard , Thomas Purcell , Daniel Galtier , Jean-Claude Muller , Pascal George , Jonathan Frost , Patrick Pasau , Corinne Rousselle , Regine Bartsch
发明人： Howard Williams , Lydia Zard , Thomas Purcell , Daniel Galtier , Jean-Claude Muller , Pascal George , Jonathan Frost , Patrick Pasau , Corinne Rousselle , Regine Bartsch
IPC分类号： A61K31/535 , A61K31/538 , A61P9/10 , A61P25/00 , A61P25/28 , A61P27/02 , A61P35/00 , C07D265/36 , C07D413/06 , C07D413/12 , C07D413/14
CPC分类号： C07D413/06 , C07D265/36 , C07D413/12 , C07D413/14
摘要： Compounds of the formula ##STR1## in which Y represents hydrogen, fluorine, chlorine, methyl or methoxy, R.sub.1 represents phenyl substituted by fluorine, methyl, methoxy, trifluoromethyl or phenyl, or R.sub.1 represents 2-thienyl, R.sub.2 represents methyl, and R.sub.3 represents (C.sub.1 -C.sub.4)-alkyl, or phenyl-(C.sub.1 -C.sub.2)-alkyl optionally substituted on the ring by 2 to 3 methoxy groups, or 2-(2-pyridyl)ethyl, or R.sub.2 and R.sub.3 form, with the adjacent nitrogen, 4-phenyl(1-piperidyl), 4-phenylmethyl(1-piperidyl), 1,2,3,4-tetrahydro-2-isoquinolyl, 6-methoxy-1,2,3,4-tetrahydro-2-isoquinolyl, 5,8-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl, 6,7-dimethoxy 1,2,3,4-tetrahydro-2-isoquinolyl, 2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl, or 7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl, and X represents carbonyl or sulphonyl, and their salts are useful as neuroprotective and antiiischaemic agents.
摘要翻译：其中Y表示氢，氟，甲基或甲氧基的式（I）化合物，R 1表示被氟，甲基，甲氧基，三氟甲基或苯基取代的苯基，或R 1表示2-噻吩基，R 2表示甲基，或R 3表示（C 1 -C 4） - 烷基或在环上任选被2至3个甲氧基取代的苯基 - （C 1 -C 2） - 烷基或2-（2-吡啶基）乙基或R 2和R 3形式，相邻的氮，4-苯基（1-哌啶基），4-苯基甲基（1-哌啶基），1,2,3,4-四氢-2-异喹啉，6-甲氧基-1,2,3,4-四氢 - 2-异喹啉基，5,8-二甲氧基-1,2,3,4-四氢-2-异喹啉，6,7-二甲氧基-1,2,3,4-四氢-2-异喹啉，2,3,4,5 - 四氢-1H-3-苯并吖庚因-3-基或7,8-二甲氧基-2,3,4,5-四氢-1H-3-苯并吖庚因-3-基，X代表羰基或磺酰基，及其盐作为神经保护和抗感染药物是有用的。

10. 发明申请

US20050036162A1 Ensuring accurate measurements for soft proofing system 审中-公开
标题翻译：确保软打样系统的准确测量
公开(公告)号：US20050036162A1
公开(公告)日：2005-02-17
申请号：US10815096
申请日：2004-03-31
申请人： Christopher Edge , Jonathan Frost
发明人： Christopher Edge , Jonathan Frost
IPC分类号： H04N1/60 , G06K15/00 , G06F3/14 , G06F11/30 , H04N17/00
CPC分类号： H04N1/6011
摘要： Techniques for providing accurate output measurement and calibration in soft proofing systems incorporate one or more features to promote controlled viewing conditions. For example, a soft proofing system is described in which an administrator can control the proofing process by limiting or restricting the ability to view an image until acceptable viewing conditions have been met. For example, the ability to view the image can be restricted until the viewing station has been calibrated using a calibration device known to support calibration of the viewing station to less than or equal to a maximum magnitude of error. With controlled viewing conditions and, more particularly, controlled calibration conditions, the soft proof reviewers obtain more uniform output. In this manner, the system can provide safeguards to ensure that the images viewed at the viewing station have acceptable color accuracy.
摘要翻译：用于在软打样系统中提供精确的输出测量和校准的技术包含一个或多个特征以促进受控的观察条件。例如，描述了一种软打样系统，其中管理员可以通过限制或限制在满足可接受的观看条件之前查看图像的能力来控制打样过程。例如，可以限制观看图像的能力，直到观察站已经使用已知支持观察站的校准的校准装置校准为小于或等于最大误差大小。具有受控的观察条件，更具体地，控制的校准条件，软证明审查者获得更均匀的输出。以这种方式，系统可以提供保护以确保在观察站观看的图像具有可接受的颜色精度。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式